Community Practice Connections™: 27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
Community Practice Connections™: 27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is organized by Physicians' Education Resource, LLC (PER).
Release Date: April 28, 2023
Expiration Date: April 28, 2024
Description:
For patients with hematologic malignancies, much progress has been accomplished; however, outcomes in many disease subsets have been suboptimal for several decades. In the past several years, a greater understanding of the biology of these diseases has led to a number of new and emerging agents that have revolutionized the treatment for these malignancies.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, held in February 2023. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with hematologic malignancies, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Assess current and emerging biomarkers to determine risk and choose therapy for patients with hematologic malignancies
• Integrate key clinical data on current treatment approaches for the management of patients with hematologic malignancies and benign hematologic disorders
• Discuss recent clinical trial results on emerging therapeutic approaches for patients with hematologic malignancies
• Describe approaches to mitigate and manage treatment-related adverse events in patients with hematologic malignancies
• Evaluate clinical implications of evolving therapeutic paradigms in hematologic malignancies